View ValuationCellaVision 향후 성장Future 기준 점검 3/6CellaVision (는) 각각 연간 19.2% 및 9.5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 19.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 18.6% 로 예상됩니다.핵심 정보19.2%이익 성장률19.16%EPS 성장률Medical Equipment 이익 성장13.3%매출 성장률9.5%향후 자기자본이익률18.59%애널리스트 커버리지Low마지막 업데이트20 Jul 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updatesReported Earnings • Jul 19Second quarter 2026 earnings released: EPS: kr1.37 (vs kr1.58 in 2Q 2025)Second quarter 2026 results: EPS: kr1.37 (down from kr1.58 in 2Q 2025). Revenue: kr199.9m (up 4.5% from 2Q 2025). Net income: kr32.6m (down 13% from 2Q 2025). Profit margin: 16% (down from 20% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Jun 15Investor sentiment improves as stock rises 22%After last week's 22% share price gain to €13.84, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 17x in the Medical Equipment industry in Germany. Total loss to shareholders of 3.1% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €20.57 per share.Recent Insider Transactions • Jun 12Founder & Director recently bought €1.5m worth of stockOn the 9th of June, Christer Fahraeus bought around 125k shares on-market at roughly €11.73 per share. This transaction amounted to 6.9% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth €2.9m. Christer has been a buyer over the last 12 months, purchasing a net total of €6.1m worth in shares.공고 • Apr 29CellaVision AB (Publ) Announces Board AppointmentsCellaVision AB (publ) at its Annual General Meeting held on April 28, 2026 resolved the election of Zlatko Rihter as new Board member. Zlatko Rihter was elected as the new Chairman of the Board of Directors.공고 • Apr 24+ 1 more updateCellaVision AB (publ) to Report First Half, 2026 Results on Jul 17, 2026CellaVision AB (publ) announced that they will report first half, 2026 results on Jul 17, 2026공고 • Apr 17CellaVision AB (publ) Announces Louise Armstrong-Denby and Mikael Worning Declines Re-ElectionCellaVision AB (publ) announced that Louise Armstrong-Denby has declined re-election; Mikael Worning has declined re-election as Chairman of the Board, but is available to serve as a Board member.공고 • Apr 10CellaVision AB (publ) to Report Q1, 2026 Results on Apr 24, 2026CellaVision AB (publ) announced that they will report Q1, 2026 results at 7:20 AM, Central European Standard Time on Apr 24, 2026공고 • Feb 06CellaVision AB (publ) announces Annual dividend, payable on May 06, 2026CellaVision AB (publ) announced Annual dividend of SEK 2.7500 per share payable on May 06, 2026, ex-date on April 29, 2026 and record date on April 30, 2026.공고 • Oct 22CellaVision AB (publ), Annual General Meeting, Apr 28, 2026CellaVision AB (publ), Annual General Meeting, Apr 28, 2026, at 15:00 W. Europe Standard Time. Location: lund Sweden공고 • May 07+ 1 more updateCellaVision AB (publ) Approves Dividend, Expects to Be Distributed by Euroclear Sweden AB on 13 May 2025CellaVision AB (publ) at the AGM held on 06 May 2025, approved dividend of SEK 2.50 per share with record date on 8 May 2025. The dividend is expected to be distributed by Euroclear Sweden AB on 13 May 2025.공고 • Feb 06+ 3 more updatesCellaVision AB (publ) to Report Fiscal Year 2025 Results on Feb 05, 2026CellaVision AB (publ) announced that they will report fiscal year 2025 results on Feb 05, 2026Valuation Update With 7 Day Price Move • Nov 01Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €19.88, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total loss to shareholders of 50% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €27.77 per share.공고 • Oct 31CellaVision AB (publ), Annual General Meeting, May 06, 2025CellaVision AB (publ), Annual General Meeting, May 06, 2025, at 15:00 W. Europe Standard Time. Location: lund SwedenBuy Or Sell Opportunity • Oct 28Now 21% undervaluedOver the last 90 days, the stock has risen 4.0% to €21.95. The fair value is estimated to be €27.75, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.6% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 27% in 2 years. Earnings are forecast to grow by 57% in the next 2 years.Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: kr1.30 (vs kr1.09 in 3Q 2023)Third quarter 2024 results: EPS: kr1.30 (up from kr1.09 in 3Q 2023). Revenue: kr178.7m (up 6.4% from 3Q 2023). Net income: kr31.1m (up 20% from 3Q 2023). Profit margin: 17% (up from 16% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Sep 01Founder & Director recently sold €2.4m worth of stockOn the 27th of August, Christer Fahraeus sold around 100k shares on-market at roughly €24.10 per share. This transaction amounted to 5.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Christer's only on-market trade for the last 12 months.Buy Or Sell Opportunity • Jul 22Now 24% undervaluedOver the last 90 days, the stock has risen 5.5% to €20.95. The fair value is estimated to be €27.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.7% over the last 3 years. Earnings per share has grown by 4.2%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 61% in the next 2 years.Reported Earnings • Jul 22Second quarter 2024 earnings released: EPS: kr1.62 (vs kr1.46 in 2Q 2023)Second quarter 2024 results: EPS: kr1.62 (up from kr1.46 in 2Q 2023). Revenue: kr187.8m (up 11% from 2Q 2023). Net income: kr38.5m (up 11% from 2Q 2023). Profit margin: 21% (in line with 2Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Jul 02Now 24% undervaluedOver the last 90 days, the stock has risen 7.9% to €21.85. The fair value is estimated to be €28.75, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 4.0%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 63% in the next 2 years.Buy Or Sell Opportunity • Jun 27Now 21% undervaluedOver the last 90 days, the stock has risen 8.3% to €22.25. The fair value is estimated to be €28.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 4.0%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 63% in the next 2 years.Valuation Update With 7 Day Price Move • May 24Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €22.65, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €28.46 per share.Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: kr1.26 (vs kr0.81 in 1Q 2023)First quarter 2024 results: EPS: kr1.26 (up from kr0.81 in 1Q 2023). Revenue: kr170.1m (up 22% from 1Q 2023). Net income: kr30.1m (up 57% from 1Q 2023). Profit margin: 18% (up from 14% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 14Full year 2023 earnings released: EPS: kr5.46 (vs kr4.96 in FY 2022)Full year 2023 results: EPS: kr5.46 (up from kr4.96 in FY 2022). Revenue: kr677.3m (up 5.9% from FY 2022). Net income: kr130.3m (up 10% from FY 2022). Profit margin: 19% (in line with FY 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Feb 24Now 20% undervaluedOver the last 90 days, the stock has risen 48% to €22.40. The fair value is estimated to be €28.01, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 4.4%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.Buy Or Sell Opportunity • Feb 13Now 21% undervaluedOver the last 90 days, the stock has risen 51% to €21.20. The fair value is estimated to be €26.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 4.4%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 22% per annum over the same time period.Declared Dividend • Feb 09Dividend of kr2.25 announcedShareholders will receive a dividend of kr2.25. Ex-date: 6th May 2024 Payment date: 13th May 2024 Dividend yield will be 9.8%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (41% earnings payout ratio) and cash flows (49% cash payout ratio). The dividend has increased by an average of 19% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 83% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Feb 08Full year 2023 earnings released: EPS: kr5.46 (vs kr4.96 in FY 2022)Full year 2023 results: EPS: kr5.46 (up from kr4.96 in FY 2022). Revenue: kr677.3m (up 5.9% from FY 2022). Net income: kr130.3m (up 10% from FY 2022). Profit margin: 19% (in line with FY 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improves as stock rises 32%After last week's 32% share price gain to €23.50, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 15% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €25.37 per share.Buy Or Sell Opportunity • Jan 26Now 25% undervaluedOver the last 90 days, the stock has risen 53% to €16.08. The fair value is estimated to be €21.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 5.8%. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.Buying Opportunity • Dec 01Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 8.1%. The fair value is estimated to be €19.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 5.8%. Revenue is forecast to grow by 31% in 2 years. Earnings is forecast to grow by 60% in the next 2 years.Valuation Update With 7 Day Price Move • Nov 03Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €12.48, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total loss to shareholders of 53% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €20.01 per share.Reported Earnings • Oct 28Third quarter 2023 earnings released: EPS: kr1.09 (vs kr0.43 in 3Q 2022)Third quarter 2023 results: EPS: kr1.09 (up from kr0.43 in 3Q 2022). Revenue: kr167.9m (up 19% from 3Q 2022). Net income: kr26.0m (up 150% from 3Q 2022). Profit margin: 16% (up from 7.4% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.공고 • Oct 26+ 5 more updatesCellaVision AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024CellaVision AB (publ) announced that they will report nine months, 2024 results on Oct 24, 2024공고 • Oct 11CellaVision AB (publ) to Report Q3, 2023 Results on Oct 25, 2023CellaVision AB (publ) announced that they will report Q3, 2023 results at 7:20 AM, Central European Standard Time on Oct 25, 2023Buying Opportunity • Sep 14Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 20%. The fair value is estimated to be €17.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 8.4%. Revenue is forecast to grow by 33% in 2 years. Earnings is forecast to grow by 95% in the next 2 years.Reported Earnings • Jul 20Second quarter 2023 earnings released: EPS: kr1.46 (vs kr1.56 in 2Q 2022)Second quarter 2023 results: EPS: kr1.46 (down from kr1.56 in 2Q 2022). Revenue: kr169.7m (down 7.6% from 2Q 2022). Net income: kr34.7m (down 6.8% from 2Q 2022). Profit margin: 21% (in line with 2Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.공고 • Jul 07CellaVision AB (publ) to Report Q2, 2023 Results on Jul 20, 2023CellaVision AB (publ) announced that they will report Q2, 2023 results at 7:20 AM, Central European Standard Time on Jul 20, 2023New Risk • Jun 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Valuation Update With 7 Day Price Move • Jun 19Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €14.96, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 27x in the Medical Equipment industry in Europe. Total loss to shareholders of 42% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.46 per share.공고 • May 06+ 1 more updateCellavision AB (Publ) Approves Dividend, Payable on May 12, 2023CellaVision AB (publ) in its AGM held on May 5, 2023 approved the proposal on a dividend of SEK 2.25 per share with record date on 9 May 2023. The dividend is expected to be paid by Euroclear Sweden AB on 12 May 2023.Upcoming Dividend • May 01Upcoming dividend of kr2.25 per share at 1.3% yieldEligible shareholders must have bought the stock before 08 May 2023. Payment date: 12 May 2023. Payout ratio is a comfortable 45% and this is well supported by cash flows. Trailing yield: 1.3%. Lower than top quartile of German dividend payers (4.5%). Lower than average of industry peers (1.6%).Valuation Update With 7 Day Price Move • Apr 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €15.28, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 27x in the Medical Equipment industry in Europe. Total loss to shareholders of 41% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €15.51 per share.Reported Earnings • Apr 16Full year 2022 earnings released: EPS: kr4.96 (vs kr5.26 in FY 2021)Full year 2022 results: EPS: kr4.96 (down from kr5.26 in FY 2021). Revenue: kr639.3m (up 13% from FY 2021). Net income: kr118.3m (down 5.6% from FY 2021). Profit margin: 19% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.Buying Opportunity • Mar 14Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 21%. The fair value is estimated to be €21.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 22% per annum over the same time period.Buying Opportunity • Feb 25Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 9.3%. The fair value is estimated to be €23.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 22% per annum over the same time period.Reported Earnings • Feb 09Full year 2022 earnings released: EPS: kr4.96 (vs kr5.26 in FY 2021)Full year 2022 results: EPS: kr4.96 (down from kr5.26 in FY 2021). Revenue: kr639.3m (up 13% from FY 2021). Net income: kr118.3m (down 5.6% from FY 2021). Profit margin: 19% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.Buying Opportunity • Feb 09Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be €22.74, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 17%.공고 • Feb 08Cellavision AB (Publ) Proposes Dividend for 2022The Board of Directors of CellaVision AB (publ) proposed an increased dividend to SEK 2.25 per share for 2022 (SEK 2.00 per share).Buying Opportunity • Jan 13Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 30%. The fair value is estimated to be €23.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 20% per annum over the same time period.Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improved over the past weekAfter last week's 17% share price gain to €23.45, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 29x in the Medical Equipment industry in Europe. Total loss to shareholders of 22% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €23.85 per share.공고 • Nov 26+ 1 more updateCellaVision AB (publ) Announces the Appointment of Emil Hjalmarsson as Chairman of the Nomination CommitteeCellaVision AB (publ) announced that Emil Hjalmarsson has been appointed Chairman of the Nomination Committee. The Nomination Committee consists of: Christer Fåhraeus, Christer Fåhraeus with Companies; Nicklas Hansen, William Demant Invest A/S; Anette Andersson, SEB Investment funds and Emil Hjalmarsson, Grenlunden CEVI AB.Valuation Update With 7 Day Price Move • Nov 02Investor sentiment deteriorated over the past weekAfter last week's 26% share price decline to €18.60, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €26.36 per share.Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: kr0.43 (vs kr1.09 in 3Q 2021)Third quarter 2022 results: EPS: kr0.43 (down from kr1.09 in 3Q 2021). Revenue: kr141.0m (up 6.9% from 3Q 2021). Net income: kr10.4m (down 60% from 3Q 2021). Profit margin: 7.4% (down from 20% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improved over the past weekAfter last week's 15% share price gain to €27.90, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 9.7% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €30.00 per share.Valuation Update With 7 Day Price Move • Sep 29Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €23.15, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 33% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €33.91 per share.공고 • Jul 28CellaVision® Launches a Complete Workflow Solution for Low-Volume Hematology LaboratoriesOn July 27, 2022, CellaVision® announces the launch of DIFF-Line TM by CellaVision, a new workflow solution for low-volume hematology laboratories, at the AACC convention in Chicago. DIFF-Line TM by CellaVision consists of three instruments for smearing, staining, and analyzing peripheral blood smears: CellaVision® DC-1, RAL® SmearBox, and RAL® StainBox. CellaVision® DC-1 is a single-slide analyzer that automates and digitizes the process of analyzing peripheral blood smears. The analyzer has an automated microscope, a high-quality digital camera, and an advanced computer system that uses artificial intelligence to locate, digitally capture, and pre-classify cells from stained blood smears. The pre-classified cells are presented on a computer screen for review and verification. The CellaVision® DC-1 was launched in 2019 and received FDA clearance in October 2020. RAL® SmearBox produces high-quality peripheral blood smears. The automated instrument uses a patented consumable to produce smears directly from a closed whole sample tube. CellaVision is introducing the RAL SmearBox to the market now July 27, 2022. RAL® StainBox stains blood smears consistently and by laboratory guidelines. The semi-automated instrument utilizes the bath method and guides the laboratory through a step-by-step staining process. Improved staining protocols contribute to ease of use and optimized DC-1 performance. The RAL® StainBox uses MCDh methanol-free stains to ensure high stain quality and reproducibility while reducing staff exposure to toxic chemicals.Reported Earnings • Jul 21Second quarter 2022 earnings released: EPS: kr1.56 (vs kr1.30 in 2Q 2021)Second quarter 2022 results: EPS: kr1.56 (up from kr1.30 in 2Q 2021). Revenue: kr183.6m (up 36% from 2Q 2021). Net income: kr37.3m (up 20% from 2Q 2021). Profit margin: 20% (down from 23% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 10%, compared to a 7.8% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.공고 • May 12+ 1 more updateCellavision AB (Publ) Announces Dividend, Payable on 18 May 2022CellaVision AB (publ) announced that the AGM held on 11 May 2022 resolved, in accordance with the Board of Directors' proposal, on a dividend of SEK 2 per share with record date on 13 May 2022. The dividend is expected to be paid by Euroclear Sweden AB on 18 May 2022.Reported Earnings • May 11First quarter 2022 earnings released: EPS: kr1.61 (vs kr1.19 in 1Q 2021)First quarter 2022 results: EPS: kr1.61 (up from kr1.19 in 1Q 2021). Revenue: kr162.4m (up 21% from 1Q 2021). Net income: kr38.4m (up 35% from 1Q 2021). Profit margin: 24% (up from 21% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 14%, compared to a 7.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Upcoming Dividend • May 05Upcoming dividend of kr2.00 per shareEligible shareholders must have bought the stock before 12 May 2022. Payment date: 18 May 2022. Payout ratio is a comfortable 38% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of German dividend payers (4.1%). Lower than average of industry peers (1.2%).Reported Earnings • Apr 23Full year 2021 earnings released: EPS: kr5.26 (vs kr3.75 in FY 2020)Full year 2021 results: EPS: kr5.26 (up from kr3.75 in FY 2020). Revenue: kr565.6m (up 20% from FY 2020). Net income: kr125.3m (up 40% from FY 2020). Profit margin: 22% (up from 19% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 17%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 3% per year.Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 15% share price gain to €29.78, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 32x in the Medical Equipment industry in Germany. Total returns to shareholders of 5.6% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €31.82 per share.공고 • Feb 06Cellavision AB (Publ) Proposes Dividend for 2021The Board of Directors of CellaVision AB (publ) proposed a dividend of SEK 2.00 per share for 2021 as compared to SEK 0.75 per share a year ago.Valuation Update With 7 Day Price Move • Feb 04Investor sentiment improved over the past weekAfter last week's 16% share price gain to €31.86, the stock trades at a forward P/E ratio of 56x. Average forward P/E is 34x in the Medical Equipment industry in Germany. Total returns to shareholders of 20% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €30.88 per share.Reported Earnings • Oct 23Third quarter 2021 earnings released: EPS kr1.09 (vs kr0.56 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr132.0m (up 50% from 3Q 2020). Net income: kr26.1m (up 96% from 3Q 2020). Profit margin: 20% (up from 15% in 3Q 2020). The increase in margin was driven by higher revenue.Recent Insider Transactions • Aug 25Founder & Director recently sold €1.1m worth of stockOn the 23rd of August, Christer Fahraeus sold around 24k shares on-market at roughly €45.43 per share. This was the largest sale by an insider in the last 3 months. This was Christer's only on-market trade for the last 12 months.Reported Earnings • Jul 22Second quarter 2021 earnings released: EPS kr1.30 (vs kr1.14 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: kr135.5m (up 15% from 2Q 2020). Net income: kr31.0m (up 14% from 2Q 2020). Profit margin: 23% (in line with 2Q 2020).Executive Departure • May 04Independent Chairman of the Board Sören Mellstig has left the companyOn the 29th of April, Sören Mellstig's tenure in the role of Independent Chairman of the Board ended. As of December 2020, Sören personally held 42.94k shares (€1.3m worth at the time). A total of 2 executives have left over the last 12 months.공고 • Apr 30CellaVision AB (publ) Approves Dividend, Payable on 6 May 2021The AGM of CellaVision AB (publ) resolved, in accordance with the Board of Directors' proposal, on a dividend of SEK 0.75 per share, with record date 3 May 2021. The dividend is expected to be paid by Euroclear Sweden AB on 6 May 2021.Upcoming Dividend • Apr 24Upcoming dividend of kr0.75 per shareEligible shareholders must have bought the stock before 30 April 2021. Payment date: 06 May 2021. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (1.0%).Reported Earnings • Apr 11Full year 2020 earnings released: EPS kr3.75 (vs kr4.16 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: kr471.4m (up 2.1% from FY 2019). Net income: kr89.5m (down 9.8% from FY 2019). Profit margin: 19% (down from 22% in FY 2019). The decrease in margin was driven by higher expenses.Analyst Estimate Surprise Post Earnings • Feb 06Revenue misses expectationsRevenue missed analyst estimates by 0.1%. Over the next year, revenue is forecast to grow 23%, compared to a 14% growth forecast for the Medical Equipment industry in Germany.Reported Earnings • Feb 06Full year 2020 earnings released: EPS kr3.75 (vs kr4.16 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: kr471.4m (up 2.1% from FY 2019). Net income: kr89.5m (down 9.8% from FY 2019). Profit margin: 19% (down from 22% in FY 2019). The decrease in margin was driven by higher expenses.Is New 90 Day High Low • Jan 22New 90-day high: €32.02The company is up 11% from its price of €28.88 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €31.95 per share.공고 • Dec 02+ 1 more updateCellaVision Announces Executive ChangesThe Board of Directors at CellaVision has appointed Simon Østergaard as President. Simon Østergaard takes on his new role in March 2021, succeeding Zlatko Rihter, who left the company on November 28. Until the date of entry, Magnus Blixt continues in his role as acting CEO and then returns to his regular role as CFO. Simon Østergaard has extensive international experience from the medical device and diagnostic (IVD) industries while holding various leadership positions covering the entire value chain from business development, research & development, quality assurance, operations to sales and marketing. Simon Østergaard joins CellaVision from Agilent Technologies where he holds the role as Vice President & General Manager for the global Pathology Division and the role as Country General Manager for Denmark. In Simon Østergaard's most recent assignment as Vice President & General Manager of the Pathology Division at Agilent Technologies, Simon Østergaard is leading its global franchise for cancer diagnostics with employees located in Copenhagen, Santa Clara, Carpinteria and Penang in addition to the global sales footprint.Is New 90 Day High Low • Oct 29New 90-day low: €27.24The company is down 5.0% from its price of €28.80 on 30 July 2020. The German market is also down 5.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Medical Equipment industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €24.69 per share.Valuation Update With 7 Day Price Move • Oct 26Market pulls back on stock over the past weekAfter last week's 16% share price decline to kr27.84, the stock is trading at a trailing P/E ratio of 77.3x, down from the previous P/E ratio of 92.2x. This compares to an average P/E of 56x in the Medical Equipment industry in Germany. Total returns to shareholders over the past year are 9.6%.공고 • Oct 15Sören Mellstig Not Stands for Re-election as Chairman of the Board of CellaVision ABThe Nomination Committee of CellaVision AB announced that the Chairman of the Board, Sören Mellstig, has declined re-election at the 2021 Annual General Meeting.Is New 90 Day High Low • Oct 01New 90-day high: €33.86The company is up 26% from its price of €26.78 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €27.15 per share.이익 및 매출 성장 예측DB:C26 - 애널리스트 향후 추정치 및 과거 재무 데이터 (SEK Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028949205145243412/31/2027870178116211412/31/202677413910719646/30/202673912998173N/A3/31/2026731134120202N/A12/31/2025759153114201N/A9/30/2025748151102195N/A6/30/2025751151119206N/A3/31/2025748152107189N/A12/31/2024723141121198N/A9/30/2024737150152229N/A6/30/2024726145183261N/A3/31/2024708141168249N/A12/31/2023677130110196N/A9/30/202362911260148N/A6/30/20236029723106N/A3/31/20236169938118N/A12/31/202263911868137N/A9/30/202265112693155N/A6/30/2022642142114173N/A3/31/202259413587171N/A12/31/202156612575160N/A9/30/202153211462139N/A6/30/20214881011387N/A3/31/2021471984482N/A12/31/2020471893771N/A9/30/2020490854071N/A6/30/20204988980107N/A3/31/202049292N/A90N/A12/31/201946299N/A126N/A9/30/2019423104N/A114N/A6/30/2019412104N/A107N/A3/31/201939197N/A119N/A12/31/201836589N/A74N/A9/30/201833076N/A91N/A6/30/201830767N/A77N/A3/31/201829463N/A69N/A12/31/201730970N/A88N/A9/30/201730670N/A93N/A6/30/201731378N/A89N/A3/31/201730075N/A86N/A12/31/201626560N/A76N/A9/30/201625457N/A54N/A6/30/201626066N/A80N/A3/31/201624655N/A59N/A12/31/201523953N/A88N/A9/30/201525049N/A70N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: C26 의 연간 예상 수익 증가율(19.2%)이 saving rate(1.9%)보다 높습니다.수익 vs 시장: C26 의 연간 수익(19.2%)이 German 시장(15.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: C26 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: C26 의 수익(연간 9.5%)이 German 시장(연간 7.2%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: C26 의 수익(연간 9.5%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: C26의 자본 수익률은 3년 후 18.6%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/27 19:59종가2026/07/27 00:00수익2026/06/30연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스CellaVision AB (publ)는 7명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Bjorn RydellABG Sundal Collier SponsoredCarl-Oscar BredengenBerenbergKristofer Liljeberg-SvenssonCarnegie Investment Bank AB4명의 분석가 더 보기
Reported Earnings • Jul 19Second quarter 2026 earnings released: EPS: kr1.37 (vs kr1.58 in 2Q 2025)Second quarter 2026 results: EPS: kr1.37 (down from kr1.58 in 2Q 2025). Revenue: kr199.9m (up 4.5% from 2Q 2025). Net income: kr32.6m (down 13% from 2Q 2025). Profit margin: 16% (down from 20% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment improves as stock rises 22%After last week's 22% share price gain to €13.84, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 17x in the Medical Equipment industry in Germany. Total loss to shareholders of 3.1% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €20.57 per share.
Recent Insider Transactions • Jun 12Founder & Director recently bought €1.5m worth of stockOn the 9th of June, Christer Fahraeus bought around 125k shares on-market at roughly €11.73 per share. This transaction amounted to 6.9% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth €2.9m. Christer has been a buyer over the last 12 months, purchasing a net total of €6.1m worth in shares.
공고 • Apr 29CellaVision AB (Publ) Announces Board AppointmentsCellaVision AB (publ) at its Annual General Meeting held on April 28, 2026 resolved the election of Zlatko Rihter as new Board member. Zlatko Rihter was elected as the new Chairman of the Board of Directors.
공고 • Apr 24+ 1 more updateCellaVision AB (publ) to Report First Half, 2026 Results on Jul 17, 2026CellaVision AB (publ) announced that they will report first half, 2026 results on Jul 17, 2026
공고 • Apr 17CellaVision AB (publ) Announces Louise Armstrong-Denby and Mikael Worning Declines Re-ElectionCellaVision AB (publ) announced that Louise Armstrong-Denby has declined re-election; Mikael Worning has declined re-election as Chairman of the Board, but is available to serve as a Board member.
공고 • Apr 10CellaVision AB (publ) to Report Q1, 2026 Results on Apr 24, 2026CellaVision AB (publ) announced that they will report Q1, 2026 results at 7:20 AM, Central European Standard Time on Apr 24, 2026
공고 • Feb 06CellaVision AB (publ) announces Annual dividend, payable on May 06, 2026CellaVision AB (publ) announced Annual dividend of SEK 2.7500 per share payable on May 06, 2026, ex-date on April 29, 2026 and record date on April 30, 2026.
공고 • Oct 22CellaVision AB (publ), Annual General Meeting, Apr 28, 2026CellaVision AB (publ), Annual General Meeting, Apr 28, 2026, at 15:00 W. Europe Standard Time. Location: lund Sweden
공고 • May 07+ 1 more updateCellaVision AB (publ) Approves Dividend, Expects to Be Distributed by Euroclear Sweden AB on 13 May 2025CellaVision AB (publ) at the AGM held on 06 May 2025, approved dividend of SEK 2.50 per share with record date on 8 May 2025. The dividend is expected to be distributed by Euroclear Sweden AB on 13 May 2025.
공고 • Feb 06+ 3 more updatesCellaVision AB (publ) to Report Fiscal Year 2025 Results on Feb 05, 2026CellaVision AB (publ) announced that they will report fiscal year 2025 results on Feb 05, 2026
Valuation Update With 7 Day Price Move • Nov 01Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to €19.88, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total loss to shareholders of 50% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €27.77 per share.
공고 • Oct 31CellaVision AB (publ), Annual General Meeting, May 06, 2025CellaVision AB (publ), Annual General Meeting, May 06, 2025, at 15:00 W. Europe Standard Time. Location: lund Sweden
Buy Or Sell Opportunity • Oct 28Now 21% undervaluedOver the last 90 days, the stock has risen 4.0% to €21.95. The fair value is estimated to be €27.75, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.6% over the last 3 years, while earnings per share has been flat. Revenue is forecast to grow by 27% in 2 years. Earnings are forecast to grow by 57% in the next 2 years.
Reported Earnings • Oct 25Third quarter 2024 earnings released: EPS: kr1.30 (vs kr1.09 in 3Q 2023)Third quarter 2024 results: EPS: kr1.30 (up from kr1.09 in 3Q 2023). Revenue: kr178.7m (up 6.4% from 3Q 2023). Net income: kr31.1m (up 20% from 3Q 2023). Profit margin: 17% (up from 16% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Sep 01Founder & Director recently sold €2.4m worth of stockOn the 27th of August, Christer Fahraeus sold around 100k shares on-market at roughly €24.10 per share. This transaction amounted to 5.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Christer's only on-market trade for the last 12 months.
Buy Or Sell Opportunity • Jul 22Now 24% undervaluedOver the last 90 days, the stock has risen 5.5% to €20.95. The fair value is estimated to be €27.55, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.7% over the last 3 years. Earnings per share has grown by 4.2%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 61% in the next 2 years.
Reported Earnings • Jul 22Second quarter 2024 earnings released: EPS: kr1.62 (vs kr1.46 in 2Q 2023)Second quarter 2024 results: EPS: kr1.62 (up from kr1.46 in 2Q 2023). Revenue: kr187.8m (up 11% from 2Q 2023). Net income: kr38.5m (up 11% from 2Q 2023). Profit margin: 21% (in line with 2Q 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Jul 02Now 24% undervaluedOver the last 90 days, the stock has risen 7.9% to €21.85. The fair value is estimated to be €28.75, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 4.0%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 63% in the next 2 years.
Buy Or Sell Opportunity • Jun 27Now 21% undervaluedOver the last 90 days, the stock has risen 8.3% to €22.25. The fair value is estimated to be €28.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 4.0%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 63% in the next 2 years.
Valuation Update With 7 Day Price Move • May 24Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €22.65, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €28.46 per share.
Reported Earnings • Apr 26First quarter 2024 earnings released: EPS: kr1.26 (vs kr0.81 in 1Q 2023)First quarter 2024 results: EPS: kr1.26 (up from kr0.81 in 1Q 2023). Revenue: kr170.1m (up 22% from 1Q 2023). Net income: kr30.1m (up 57% from 1Q 2023). Profit margin: 18% (up from 14% in 1Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 14Full year 2023 earnings released: EPS: kr5.46 (vs kr4.96 in FY 2022)Full year 2023 results: EPS: kr5.46 (up from kr4.96 in FY 2022). Revenue: kr677.3m (up 5.9% from FY 2022). Net income: kr130.3m (up 10% from FY 2022). Profit margin: 19% (in line with FY 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Feb 24Now 20% undervaluedOver the last 90 days, the stock has risen 48% to €22.40. The fair value is estimated to be €28.01, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 4.4%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.
Buy Or Sell Opportunity • Feb 13Now 21% undervaluedOver the last 90 days, the stock has risen 51% to €21.20. The fair value is estimated to be €26.98, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 4.4%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 22% per annum over the same time period.
Declared Dividend • Feb 09Dividend of kr2.25 announcedShareholders will receive a dividend of kr2.25. Ex-date: 6th May 2024 Payment date: 13th May 2024 Dividend yield will be 9.8%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is well covered by both earnings (41% earnings payout ratio) and cash flows (49% cash payout ratio). The dividend has increased by an average of 19% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 83% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Feb 08Full year 2023 earnings released: EPS: kr5.46 (vs kr4.96 in FY 2022)Full year 2023 results: EPS: kr5.46 (up from kr4.96 in FY 2022). Revenue: kr677.3m (up 5.9% from FY 2022). Net income: kr130.3m (up 10% from FY 2022). Profit margin: 19% (in line with FY 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improves as stock rises 32%After last week's 32% share price gain to €23.50, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 15% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €25.37 per share.
Buy Or Sell Opportunity • Jan 26Now 25% undervaluedOver the last 90 days, the stock has risen 53% to €16.08. The fair value is estimated to be €21.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 5.8%. For the next 3 years, revenue is forecast to grow by 13% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.
Buying Opportunity • Dec 01Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 8.1%. The fair value is estimated to be €19.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 5.8%. Revenue is forecast to grow by 31% in 2 years. Earnings is forecast to grow by 60% in the next 2 years.
Valuation Update With 7 Day Price Move • Nov 03Investor sentiment improves as stock rises 18%After last week's 18% share price gain to €12.48, the stock trades at a forward P/E ratio of 23x. Average forward P/E is 23x in the Medical Equipment industry in Germany. Total loss to shareholders of 53% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €20.01 per share.
Reported Earnings • Oct 28Third quarter 2023 earnings released: EPS: kr1.09 (vs kr0.43 in 3Q 2022)Third quarter 2023 results: EPS: kr1.09 (up from kr0.43 in 3Q 2022). Revenue: kr167.9m (up 19% from 3Q 2022). Net income: kr26.0m (up 150% from 3Q 2022). Profit margin: 16% (up from 7.4% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings.
공고 • Oct 26+ 5 more updatesCellaVision AB (publ) to Report Nine Months, 2024 Results on Oct 24, 2024CellaVision AB (publ) announced that they will report nine months, 2024 results on Oct 24, 2024
공고 • Oct 11CellaVision AB (publ) to Report Q3, 2023 Results on Oct 25, 2023CellaVision AB (publ) announced that they will report Q3, 2023 results at 7:20 AM, Central European Standard Time on Oct 25, 2023
Buying Opportunity • Sep 14Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 20%. The fair value is estimated to be €17.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 8.4%. Revenue is forecast to grow by 33% in 2 years. Earnings is forecast to grow by 95% in the next 2 years.
Reported Earnings • Jul 20Second quarter 2023 earnings released: EPS: kr1.46 (vs kr1.56 in 2Q 2022)Second quarter 2023 results: EPS: kr1.46 (down from kr1.56 in 2Q 2022). Revenue: kr169.7m (down 7.6% from 2Q 2022). Net income: kr34.7m (down 6.8% from 2Q 2022). Profit margin: 21% (in line with 2Q 2022). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
공고 • Jul 07CellaVision AB (publ) to Report Q2, 2023 Results on Jul 20, 2023CellaVision AB (publ) announced that they will report Q2, 2023 results at 7:20 AM, Central European Standard Time on Jul 20, 2023
New Risk • Jun 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Valuation Update With 7 Day Price Move • Jun 19Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to €14.96, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 27x in the Medical Equipment industry in Europe. Total loss to shareholders of 42% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.46 per share.
공고 • May 06+ 1 more updateCellavision AB (Publ) Approves Dividend, Payable on May 12, 2023CellaVision AB (publ) in its AGM held on May 5, 2023 approved the proposal on a dividend of SEK 2.25 per share with record date on 9 May 2023. The dividend is expected to be paid by Euroclear Sweden AB on 12 May 2023.
Upcoming Dividend • May 01Upcoming dividend of kr2.25 per share at 1.3% yieldEligible shareholders must have bought the stock before 08 May 2023. Payment date: 12 May 2023. Payout ratio is a comfortable 45% and this is well supported by cash flows. Trailing yield: 1.3%. Lower than top quartile of German dividend payers (4.5%). Lower than average of industry peers (1.6%).
Valuation Update With 7 Day Price Move • Apr 27Investor sentiment improves as stock rises 15%After last week's 15% share price gain to €15.28, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 27x in the Medical Equipment industry in Europe. Total loss to shareholders of 41% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €15.51 per share.
Reported Earnings • Apr 16Full year 2022 earnings released: EPS: kr4.96 (vs kr5.26 in FY 2021)Full year 2022 results: EPS: kr4.96 (down from kr5.26 in FY 2021). Revenue: kr639.3m (up 13% from FY 2021). Net income: kr118.3m (down 5.6% from FY 2021). Profit margin: 19% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings.
Buying Opportunity • Mar 14Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 21%. The fair value is estimated to be €21.82, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 22% per annum over the same time period.
Buying Opportunity • Feb 25Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 9.3%. The fair value is estimated to be €23.54, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 22% per annum over the same time period.
Reported Earnings • Feb 09Full year 2022 earnings released: EPS: kr4.96 (vs kr5.26 in FY 2021)Full year 2022 results: EPS: kr4.96 (down from kr5.26 in FY 2021). Revenue: kr639.3m (up 13% from FY 2021). Net income: kr118.3m (down 5.6% from FY 2021). Profit margin: 19% (down from 22% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings.
Buying Opportunity • Feb 09Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 12%. The fair value is estimated to be €22.74, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 17%.
공고 • Feb 08Cellavision AB (Publ) Proposes Dividend for 2022The Board of Directors of CellaVision AB (publ) proposed an increased dividend to SEK 2.25 per share for 2022 (SEK 2.00 per share).
Buying Opportunity • Jan 13Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 30%. The fair value is estimated to be €23.85, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 14%. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 20% per annum over the same time period.
Valuation Update With 7 Day Price Move • Dec 15Investor sentiment improved over the past weekAfter last week's 17% share price gain to €23.45, the stock trades at a forward P/E ratio of 41x. Average forward P/E is 29x in the Medical Equipment industry in Europe. Total loss to shareholders of 22% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €23.85 per share.
공고 • Nov 26+ 1 more updateCellaVision AB (publ) Announces the Appointment of Emil Hjalmarsson as Chairman of the Nomination CommitteeCellaVision AB (publ) announced that Emil Hjalmarsson has been appointed Chairman of the Nomination Committee. The Nomination Committee consists of: Christer Fåhraeus, Christer Fåhraeus with Companies; Nicklas Hansen, William Demant Invest A/S; Anette Andersson, SEB Investment funds and Emil Hjalmarsson, Grenlunden CEVI AB.
Valuation Update With 7 Day Price Move • Nov 02Investor sentiment deteriorated over the past weekAfter last week's 26% share price decline to €18.60, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 27x in the Medical Equipment industry in Germany. Total loss to shareholders of 28% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €26.36 per share.
Reported Earnings • Oct 27Third quarter 2022 earnings released: EPS: kr0.43 (vs kr1.09 in 3Q 2021)Third quarter 2022 results: EPS: kr0.43 (down from kr1.09 in 3Q 2021). Revenue: kr141.0m (up 6.9% from 3Q 2021). Net income: kr10.4m (down 60% from 3Q 2021). Profit margin: 7.4% (down from 20% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Oct 18Investor sentiment improved over the past weekAfter last week's 15% share price gain to €27.90, the stock trades at a forward P/E ratio of 45x. Average forward P/E is 25x in the Medical Equipment industry in Germany. Total loss to shareholders of 9.7% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €30.00 per share.
Valuation Update With 7 Day Price Move • Sep 29Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €23.15, the stock trades at a forward P/E ratio of 36x. Average forward P/E is 24x in the Medical Equipment industry in Germany. Total loss to shareholders of 33% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €33.91 per share.
공고 • Jul 28CellaVision® Launches a Complete Workflow Solution for Low-Volume Hematology LaboratoriesOn July 27, 2022, CellaVision® announces the launch of DIFF-Line TM by CellaVision, a new workflow solution for low-volume hematology laboratories, at the AACC convention in Chicago. DIFF-Line TM by CellaVision consists of three instruments for smearing, staining, and analyzing peripheral blood smears: CellaVision® DC-1, RAL® SmearBox, and RAL® StainBox. CellaVision® DC-1 is a single-slide analyzer that automates and digitizes the process of analyzing peripheral blood smears. The analyzer has an automated microscope, a high-quality digital camera, and an advanced computer system that uses artificial intelligence to locate, digitally capture, and pre-classify cells from stained blood smears. The pre-classified cells are presented on a computer screen for review and verification. The CellaVision® DC-1 was launched in 2019 and received FDA clearance in October 2020. RAL® SmearBox produces high-quality peripheral blood smears. The automated instrument uses a patented consumable to produce smears directly from a closed whole sample tube. CellaVision is introducing the RAL SmearBox to the market now July 27, 2022. RAL® StainBox stains blood smears consistently and by laboratory guidelines. The semi-automated instrument utilizes the bath method and guides the laboratory through a step-by-step staining process. Improved staining protocols contribute to ease of use and optimized DC-1 performance. The RAL® StainBox uses MCDh methanol-free stains to ensure high stain quality and reproducibility while reducing staff exposure to toxic chemicals.
Reported Earnings • Jul 21Second quarter 2022 earnings released: EPS: kr1.56 (vs kr1.30 in 2Q 2021)Second quarter 2022 results: EPS: kr1.56 (up from kr1.30 in 2Q 2021). Revenue: kr183.6m (up 36% from 2Q 2021). Net income: kr37.3m (up 20% from 2Q 2021). Profit margin: 20% (down from 23% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 10%, compared to a 7.8% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
공고 • May 12+ 1 more updateCellavision AB (Publ) Announces Dividend, Payable on 18 May 2022CellaVision AB (publ) announced that the AGM held on 11 May 2022 resolved, in accordance with the Board of Directors' proposal, on a dividend of SEK 2 per share with record date on 13 May 2022. The dividend is expected to be paid by Euroclear Sweden AB on 18 May 2022.
Reported Earnings • May 11First quarter 2022 earnings released: EPS: kr1.61 (vs kr1.19 in 1Q 2021)First quarter 2022 results: EPS: kr1.61 (up from kr1.19 in 1Q 2021). Revenue: kr162.4m (up 21% from 1Q 2021). Net income: kr38.4m (up 35% from 1Q 2021). Profit margin: 24% (up from 21% in 1Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 14%, compared to a 7.1% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Upcoming Dividend • May 05Upcoming dividend of kr2.00 per shareEligible shareholders must have bought the stock before 12 May 2022. Payment date: 18 May 2022. Payout ratio is a comfortable 38% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of German dividend payers (4.1%). Lower than average of industry peers (1.2%).
Reported Earnings • Apr 23Full year 2021 earnings released: EPS: kr5.26 (vs kr3.75 in FY 2020)Full year 2021 results: EPS: kr5.26 (up from kr3.75 in FY 2020). Revenue: kr565.6m (up 20% from FY 2020). Net income: kr125.3m (up 40% from FY 2020). Profit margin: 22% (up from 19% in FY 2020). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 17%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has increased by 6% per year whereas the company’s share price has increased by 3% per year.
Valuation Update With 7 Day Price Move • Mar 15Investor sentiment improved over the past weekAfter last week's 15% share price gain to €29.78, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 32x in the Medical Equipment industry in Germany. Total returns to shareholders of 5.6% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €31.82 per share.
공고 • Feb 06Cellavision AB (Publ) Proposes Dividend for 2021The Board of Directors of CellaVision AB (publ) proposed a dividend of SEK 2.00 per share for 2021 as compared to SEK 0.75 per share a year ago.
Valuation Update With 7 Day Price Move • Feb 04Investor sentiment improved over the past weekAfter last week's 16% share price gain to €31.86, the stock trades at a forward P/E ratio of 56x. Average forward P/E is 34x in the Medical Equipment industry in Germany. Total returns to shareholders of 20% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €30.88 per share.
Reported Earnings • Oct 23Third quarter 2021 earnings released: EPS kr1.09 (vs kr0.56 in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: kr132.0m (up 50% from 3Q 2020). Net income: kr26.1m (up 96% from 3Q 2020). Profit margin: 20% (up from 15% in 3Q 2020). The increase in margin was driven by higher revenue.
Recent Insider Transactions • Aug 25Founder & Director recently sold €1.1m worth of stockOn the 23rd of August, Christer Fahraeus sold around 24k shares on-market at roughly €45.43 per share. This was the largest sale by an insider in the last 3 months. This was Christer's only on-market trade for the last 12 months.
Reported Earnings • Jul 22Second quarter 2021 earnings released: EPS kr1.30 (vs kr1.14 in 2Q 2020)The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: kr135.5m (up 15% from 2Q 2020). Net income: kr31.0m (up 14% from 2Q 2020). Profit margin: 23% (in line with 2Q 2020).
Executive Departure • May 04Independent Chairman of the Board Sören Mellstig has left the companyOn the 29th of April, Sören Mellstig's tenure in the role of Independent Chairman of the Board ended. As of December 2020, Sören personally held 42.94k shares (€1.3m worth at the time). A total of 2 executives have left over the last 12 months.
공고 • Apr 30CellaVision AB (publ) Approves Dividend, Payable on 6 May 2021The AGM of CellaVision AB (publ) resolved, in accordance with the Board of Directors' proposal, on a dividend of SEK 0.75 per share, with record date 3 May 2021. The dividend is expected to be paid by Euroclear Sweden AB on 6 May 2021.
Upcoming Dividend • Apr 24Upcoming dividend of kr0.75 per shareEligible shareholders must have bought the stock before 30 April 2021. Payment date: 06 May 2021. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (1.0%).
Reported Earnings • Apr 11Full year 2020 earnings released: EPS kr3.75 (vs kr4.16 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: kr471.4m (up 2.1% from FY 2019). Net income: kr89.5m (down 9.8% from FY 2019). Profit margin: 19% (down from 22% in FY 2019). The decrease in margin was driven by higher expenses.
Analyst Estimate Surprise Post Earnings • Feb 06Revenue misses expectationsRevenue missed analyst estimates by 0.1%. Over the next year, revenue is forecast to grow 23%, compared to a 14% growth forecast for the Medical Equipment industry in Germany.
Reported Earnings • Feb 06Full year 2020 earnings released: EPS kr3.75 (vs kr4.16 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: kr471.4m (up 2.1% from FY 2019). Net income: kr89.5m (down 9.8% from FY 2019). Profit margin: 19% (down from 22% in FY 2019). The decrease in margin was driven by higher expenses.
Is New 90 Day High Low • Jan 22New 90-day high: €32.02The company is up 11% from its price of €28.88 on 23 October 2020. The German market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €31.95 per share.
공고 • Dec 02+ 1 more updateCellaVision Announces Executive ChangesThe Board of Directors at CellaVision has appointed Simon Østergaard as President. Simon Østergaard takes on his new role in March 2021, succeeding Zlatko Rihter, who left the company on November 28. Until the date of entry, Magnus Blixt continues in his role as acting CEO and then returns to his regular role as CFO. Simon Østergaard has extensive international experience from the medical device and diagnostic (IVD) industries while holding various leadership positions covering the entire value chain from business development, research & development, quality assurance, operations to sales and marketing. Simon Østergaard joins CellaVision from Agilent Technologies where he holds the role as Vice President & General Manager for the global Pathology Division and the role as Country General Manager for Denmark. In Simon Østergaard's most recent assignment as Vice President & General Manager of the Pathology Division at Agilent Technologies, Simon Østergaard is leading its global franchise for cancer diagnostics with employees located in Copenhagen, Santa Clara, Carpinteria and Penang in addition to the global sales footprint.
Is New 90 Day High Low • Oct 29New 90-day low: €27.24The company is down 5.0% from its price of €28.80 on 30 July 2020. The German market is also down 5.0% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it underperformed the Medical Equipment industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €24.69 per share.
Valuation Update With 7 Day Price Move • Oct 26Market pulls back on stock over the past weekAfter last week's 16% share price decline to kr27.84, the stock is trading at a trailing P/E ratio of 77.3x, down from the previous P/E ratio of 92.2x. This compares to an average P/E of 56x in the Medical Equipment industry in Germany. Total returns to shareholders over the past year are 9.6%.
공고 • Oct 15Sören Mellstig Not Stands for Re-election as Chairman of the Board of CellaVision ABThe Nomination Committee of CellaVision AB announced that the Chairman of the Board, Sören Mellstig, has declined re-election at the 2021 Annual General Meeting.
Is New 90 Day High Low • Oct 01New 90-day high: €33.86The company is up 26% from its price of €26.78 on 03 July 2020. The German market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is up 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €27.15 per share.